Kymera Therapeutics, Inc. · NASDAQ:KYMR
Booth Bruce sold 478,198 Kymera Therapeutics, Inc. shares (Form 4)
Traded Jun 17 to Jun 22, 2026 · Filed Jun 22, 2026
From Jun 17 to Jun 22, 2026, Booth Bruce (Director) sold 478,198 Kymera Therapeutics, Inc. shares at an average US$94.72 for US$45.3M under a trading plan, leaving 617,663 shares. Filed Jun 22, 2026 (Form 4).
- Sold
- 478,198 shares
- Price
- US$94.72 average (US$89.98 to US$102.48)
- Value
- US$45.3M
- Holding after
- 617,663 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | Common Stock | Option exercise | 11,741 | US$20.00 | 11,741 | Direct |
| Jun 17, 2026 | Common Stock | Sale | 11,741 | US$89.98 | 0 | Direct |
| Jun 17, 2026 | Common Stock | Sale | 92,169 | US$90.38 | 3,807,660 | Indirect |
| Jun 17, 2026 | Common Stock | Sale | 12,902 | US$90.38 | 662,042 | Indirect |
| Jun 18, 2026 | Common Stock | Sale | 62,897 | US$90.48 | 3,744,763 | Indirect |
| Jun 18, 2026 | Common Stock | Sale | 32,359 | US$91.85 | 3,712,404 | Indirect |
| Jun 18, 2026 | Common Stock | Sale | 5,672 | US$92.16 | 3,706,732 | Indirect |
| Jun 18, 2026 | Common Stock | Sale | 8,809 | US$90.48 | 653,233 | Indirect |
| Jun 18, 2026 | Common Stock | Sale | 4,526 | US$91.85 | 648,707 | Indirect |
| Jun 18, 2026 | Common Stock | Sale | 793 | US$92.16 | 647,914 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 14,921 | US$92.14 | 3,691,811 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 2,035 | US$94.48 | 3,689,776 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 11,783 | US$95.12 | 3,677,993 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 20,903 | US$96.24 | 3,657,090 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 16,084 | US$97.68 | 3,641,006 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 25,976 | US$98.58 | 3,615,030 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 52,442 | US$99.57 | 3,562,588 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 56,348 | US$100.17 | 3,506,240 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 6,597 | US$101.61 | 3,499,643 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 8,990 | US$102.48 | 3,490,653 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 2,179 | US$92.14 | 645,735 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 286 | US$94.48 | 645,449 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 1,648 | US$95.12 | 643,801 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 2,919 | US$96.24 | 640,882 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 2,247 | US$97.68 | 638,635 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 3,603 | US$98.58 | 635,032 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 7,319 | US$99.57 | 627,713 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 7,879 | US$100.17 | 619,834 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 918 | US$101.61 | 618,916 | Indirect |
| Jun 22, 2026 | Common Stock | Sale | 1,253 | US$102.48 | 617,663 | Indirect |
Source
Related
- Kymera Therapeutics, Inc.
- Booth Bruce
- Kymera Therapeutics, Inc. shareholders
- Form 4/A · Booth Bruce · Jul 2, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Mainolfi Nello · Oct 1, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Sep 8, 2026
- Form 4 · Adams Brian · Sep 4, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Atlas Venture Fund X, L.P. · Aug 13, 2026